Press Releases

GI Dynamics, Inc. Announces Completion of A$57.5 Million Private Placement And Launch of Share Purchase Plan

Lexington, Mass., United States and Sydney, Australia – 3 July 2013 AEST – GI Dynamics, Inc. (ASX: GID) (“GI Dynamics” or the “Company”) is pleased to announce that it has received commitments for an oversubscribed private placement of 108.5 million fully paid CHESS Depositary Interests (CDIs) at...

read more

GI Dynamics, Inc. Appoints Distributor for the Middle East

LEXINGTON, Massachusetts and SYDNEY, Australia – 26 June 2013 – GI Dynamics, Inc. (ASX: GID) today announced that it has appointed Al-Nozha Medical Est., based in Jeddah, Saudi Arabia, as the distributor of EndoBarrier®, GI Dynamics’ proprietary treatment for type 2 diabetes and/or obesity, in...

read more

French Government Approves Two-Year Clinical Utility Study of EndoBarrier® Therapy

 ENDOMETAB will enroll 174 subjects at multiple sites throughout France LEXINGTON, Massachusetts & SYDNEY – 19 June 2013 – GI Dynamics, Inc. (ASX: GID) today announced that the French Ministry of Social Affairs and Health has approved a large, randomized, multi-center clinical utility study of...

read more

GI Dynamics Announces New Commercial Centres Offering EndoBarrier® Therapy in the European Union

New Centres in Spain, Switzerland and Germany Bring Total Number to 37 Globally LEXINGTON, Massachusetts and SYDNEY, Australia – 18 June 2013 – GI Dynamics, Inc. (ASX: GID) today announced that five prestigious new centres in Europe have begun offering EndoBarrier® Therapy, the Company’s...

read more

Data on GI Dynamics’ EndoBarrier® Therapy Presented at the ADA 72nd Scientific Sessions

— Data released on six month randomized, multi-center trial of EndoBarrier versus control in obese, type 2 diabetic subjects —  Lexington, Massachusetts, United States and Sydney, Australia – June 11, 2012 – GI Dynamics, Inc. (ASX: GID), a company pioneering the development of...

read more

2013 Annual General Meeting Access for Participants by Webcast and Conference Call

Lexington, Massachusetts, and Sydney, Australia – 13 May 2013 – GI Dynamics, Inc. (GI Dynamics or the Company) (ASX: GID) will hold its 2013 Annual General Meeting of Stockholders at 2:30 p.m. AEST on Monday, 20 May 2013 (12:30 a.m. U.S. EDT on Monday, May 20, 2013) at the AGL Theatre in the...

read more

GI Dynamics, Inc. Appoints David Maggs, M.D. as Chief Medical Officer

LEXINGTON, Massachusetts & SYDNEY – April 30, 2013 – GI Dynamics, Inc. (ASX: GID) today announced the appointment of David Maggs, M.D. to the position of chief medical officer. In this role, Dr. Maggs will oversee clinical development and medical affairs for the Company’s lead...

read more

GI Dynamics, Inc. Reports on Progress of the ENDO Trial

LEXINGTON, Massachusetts & SYDNEY, Australia – 25 April 2013 – GI Dynamics, Inc. (ASX: GID) today announced an update on the status of the ENDO Trial, its U.S. multi-center, pivotal clinical trial of EndoBarrier® for the treatment of patients who have uncontrolled type 2 diabetes and are...

read more

EndoBarrier® Therapy Named Product of the Year by BioSpectrum Asia

LEXINGTON, Massachusetts & SYDNEY – 18 March 2013 – GI Dynamics, Inc. (ASX: GID) today announced that EndoBarrier® Therapy, the Company’s non-surgical, non-pharmaceutical treatment for type 2 diabetes and/or obesity, was selected by an independent panel of international life sciences experts...

read more

EndoBarrier® Therapy Named Product of the Year by BioSpectrum Asia

LEXINGTON, Massachusetts & SYDNEY – 18 March 2013 – GI Dynamics, Inc. (ASX: GID) today announced that EndoBarrier® Therapy, the Company’s non-surgical, non-pharmaceutical treatment for type 2 diabetes and/or obesity, was selected by an independent panel of international life sciences experts...

read more
Page 10 of 17« First...89101112...Last »